These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 24127453)

  • 1. Reply to F. Ades.
    Guan Z
    J Clin Oncol; 2013 Nov; 31(33):4272. PubMed ID: 24127453
    [No Abstract]   [Full Text] [Related]  

  • 2. Lapatinib versus placebo added to paclitaxel in first-line human epidermal growth factor receptor 2-positive metastatic breast cancer: ethical lessons not learned from Africa.
    Ades F
    J Clin Oncol; 2013 Nov; 31(33):4271. PubMed ID: 24127451
    [No Abstract]   [Full Text] [Related]  

  • 3. Targeted therapies: HER2-positive breast cancer-sifting through many good options.
    Krop IE
    Nat Rev Clin Oncol; 2013 Jun; 10(6):312-3. PubMed ID: 23629473
    [No Abstract]   [Full Text] [Related]  

  • 4. Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast cancer.
    Guan Z; Xu B; DeSilvio ML; Shen Z; Arpornwirat W; Tong Z; Lorvidhaya V; Jiang Z; Yang J; Makhson A; Leung WL; Russo MW; Newstat B; Wang L; Chen G; Oliva C; Gomez H
    J Clin Oncol; 2013 Jun; 31(16):1947-53. PubMed ID: 23509322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Of mice and (wo)men: is this any way to test a new drug?
    Haddad TC; Yee D
    J Clin Oncol; 2008 Feb; 26(6):830-2. PubMed ID: 18281652
    [No Abstract]   [Full Text] [Related]  

  • 6. [Novel target therapies used in breast cancer management].
    Semiglazova TIu; Semiglazov VV; Filatova LV; Gershanovich ML; Chudenko VA; Latipova DKh; Luk'ianchikova VS; Dashian GA; Paltuev RM
    Vopr Onkol; 2011; 57(5):592-600. PubMed ID: 22238928
    [No Abstract]   [Full Text] [Related]  

  • 7. Better treatments needed for breast cancer brain metastases.
    Lin NU
    Lancet Oncol; 2015 Dec; 16(16):1583-4. PubMed ID: 26596673
    [No Abstract]   [Full Text] [Related]  

  • 8. The Dual Role of Tumor-Infiltrating Lymphocytes in Human Epidermal Growth Factor Receptor 2-Positive Primary Breast Cancer: Two Sides of the Same Coin?
    Loibl S
    JAMA Oncol; 2015 Jul; 1(4):455-6. PubMed ID: 26181253
    [No Abstract]   [Full Text] [Related]  

  • 9. A systematic review of dual targeting in HER2-positive breast cancer.
    Kümler I; Tuxen MK; Nielsen DL
    Cancer Treat Rev; 2014 Mar; 40(2):259-70. PubMed ID: 24080156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lapatinib moves forward in inflammatory and early HER2-positive breast cancer trials.
    Tuma RS
    J Natl Cancer Inst; 2007 Mar; 99(5):348-9. PubMed ID: 17341725
    [No Abstract]   [Full Text] [Related]  

  • 11. Targeted therapy for metastatic breast cancer.
    Muss HB
    N Engl J Med; 2006 Dec; 355(26):2783-5. PubMed ID: 17192546
    [No Abstract]   [Full Text] [Related]  

  • 12. Lapatinib in breast cancer: clinical experiences and future perspectives.
    Giampaglia M; Chiuri VE; Tinelli A; De Laurentiis M; Silvestris N; Lorusso V
    Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S72-9. PubMed ID: 21129615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hints of future progress for HER-2 breast cancer.
    Twombly R
    J Natl Cancer Inst; 2011 Apr; 103(7):535-7. PubMed ID: 21436059
    [No Abstract]   [Full Text] [Related]  

  • 14. TEACH: Tykerb evaluation after chemotherapy.
    Moy B; Goss PE
    Clin Breast Cancer; 2007 Feb; 7(6):489-92. PubMed ID: 17386127
    [No Abstract]   [Full Text] [Related]  

  • 15. Acquired resistance to small molecule ErbB2 tyrosine kinase inhibitors.
    Chen FL; Xia W; Spector NL
    Clin Cancer Res; 2008 Nov; 14(21):6730-4. PubMed ID: 18980964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual HER2 targeting for early breast cancer.
    Johnston SR
    Lancet Oncol; 2013 Nov; 14(12):1145-6. PubMed ID: 24095298
    [No Abstract]   [Full Text] [Related]  

  • 17. Lapatinib in second-line treatment for metastatic breast cancer: rapid clinical benefit and long-term response.
    De Tursi M; Carella C
    Tumori; 2013; 99(6):261e-3e. PubMed ID: 24503799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Associations of tyrosine kinase inhibitors with chemotherapy].
    Bréchot JM
    Rev Pneumol Clin; 2007 Jan; 63(1 Pt 2):2S12-3. PubMed ID: 17242638
    [No Abstract]   [Full Text] [Related]  

  • 19. Lapatinib: clinical benefit in patients with HER 2-positive advanced breast cancer.
    Kroep JR; Linn SC; Boven E; Bloemendal HJ; Baas J; Mandjes IA; van den Bosch J; Smit WM; de Graaf H; Schröder CP; Vermeulen GJ; Hop WC; Nortier JW
    Neth J Med; 2010 Sep; 68(9):371-6. PubMed ID: 20876920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A single-arm phase II trial of first-line paclitaxel in combination with lapatinib in HER2-overexpressing metastatic breast cancer.
    Jagiello-Gruszfeld A; Tjulandin S; Dobrovolskaya N; Manikhas A; Pienkowski T; DeSilvio M; Ridderheim M; Abbey R
    Oncology; 2010; 79(1-2):129-35. PubMed ID: 21088439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.